- The stock price of 180 Life Sciences Corp (NASDAQ: ATNF) increased by over 7% during intraday trading today. This is why it happened.
The stock price of 180 Life Sciences Corp (NASDAQ: ATNF) – a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis, and pain – increased by over 7% during intraday trading today. Investors are responding to positively to 180 Life Sciences announcing that Professor Jagdeep Nanchahal from the University of Oxford, a co-founder of 180 Life Sciences, will be presenting a keynote address entitled ‘Re-purposing anti-TNF for Dupuytren’s Disease’ at the 2021 International Dupuytren Symposium on Wednesday, December 1, 2021, at 3 pm EST.
Professor Nanchahal is going to present his work on unraveling the molecular mechanisms underlying the pathogenesis of Dupuytren’s disease leading to the identification of anti-tumor necrosis factor (TNF) as a potential therapeutic target. And he will also present the phase 2a clinical trial data to identify the optimal dose and top-line data for the recently completed phase 2b clinical trial on efficacy for patients with early-stage disease.
Plus the company also announced that it currently expects that the dosage of the first patient in its planned frozen shoulder clinical trial will take place during the 1st or 2nd quarter of 2022.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.